Table 1.
Clinicopathological features of all patients included in this study
| Clinicopathological parameter | No. of patients (n = 98) (%) |
|---|---|
| Gender | |
| Male | 72 (73.5) |
| Female | 26 (26.5) |
| Tumour stage | |
| T1 | 37 (37.8) |
| T2 | 18 (18.4) |
| T3 | 16 (16.3) |
| T4 | 27 (27.6) |
| N stage | |
| N0 | 63 (64.3) |
| N1 | 19 (19.4) |
| N2 | 16 (16.3) |
| Tumour grade | |
| I | 22 (22.4) |
| II | 49 (50.0) |
| III | 27 (27.6) |
| p53 staining | |
| Negative (<10%) | 48 (49.0) |
| Positive (≥10%) | 41 (41.8) |
| Unrepresentative | 9 (9.2) |
| GLI‐1 staining | |
| Negative (<5%) | 41 (41.8) |
| Positive (≥5%) | 52 (53.1) |
| Unrepresentative | 5 (5.1) |
| SMO staining | |
| Negative (<5%) | 71 (72.4) |
| Positive (≥5%) | 20 (20.4) |
| Unrepresentative | 7 (7.1) |
| p16 staining | |
| Negative (<1%) | 65 (66.3) |
| Positive (≥1%) | 28 (28.6) |
| Unrepresentative | 5 (5.1) |
| Localisation | |
| Palate | 4 (4.1) |
| Lip | 18 (18.4) |
| Base of the mouth | 56 (57.1) |
| Tonsil | 3 (3.1) |
| Buccal | 1 (1.0) |
| Tongue | 16 (16.3) |